Keyphrases
Lung Tissue
100%
Peroxisome Proliferator-activated Receptor
100%
Innate Inflammatory Response
100%
Inflammation
27%
Mode of Action
27%
LPS-induced Inflammation
18%
Transrepression
18%
Pulmonary Artery
18%
Bronchi
18%
Polar Interactions
18%
Lung Inflammation
9%
Metabolism
9%
Anti-inflammatory Effect
9%
Nuclear Receptor
9%
Co-incubation
9%
Mechanism of Action
9%
Molecular Mechanism
9%
Chemistry Method
9%
Ligand Binding
9%
Functional Outcome
9%
GW0742
9%
Computational Chemistry
9%
Binding Profile
9%
Rat Lung
9%
Novel Therapies
9%
GSK3787
9%
Binding Pocket
9%
Signal Control
9%
Binding Energy
9%
GSK0660
9%
Pulmonary Parenchyma
9%
Delta Mechanism
9%
Inflammatory-related Diseases
9%
Inflammatory Lung Disease
9%
Inflammation Model
9%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammation
100%
Peroxisome Proliferator Activated Receptor
100%
Peroxisome Proliferator Activated Receptor Delta
100%
Pneumonia
18%
Lipopolysaccharide-Induced Inflammation
18%
Anti-Inflammatory Drug
9%
Antiinflammatory Activity
9%
Cell Nucleus Receptor
9%
Disease
9%
[4 [2 (3 Fluoro 4 Trifluoromethylphenyl) 4 Methyl 5 Thiazolylmethylthio] 2 Methylphenoxy]acetic Acid
9%
Delta Opiate Receptor Agonist
9%
Delta Opiate Receptor Antagonist
9%
3 [(4 Anilino 2 Methoxyphenyl)sulfamoyl] 2 Thenoic Acid Methyl Ester
9%
Immunology and Microbiology
Inflammation Response
100%
Peroxisome
100%
Agonist
36%
Pulmonary Artery
18%
Parenchyma
18%
Antiinflammatory Activity
9%
Pulmonary Inflammation
9%
Ligand Binding
9%